
This role will be a senior counsel advising the APAC commercial team on matters of commercial law across APAC, with a focus on China. The role will be a senior member of the team in China and will also be a senior member of the trade compliance team managed from the UK. The role will provide pragmatic legal advice on a broad range of transactions to support the continued growth and expansion of Oxford Nanopore in APAC. The role will work closely with the Leadership, Business Manager, China, Finance, and HR on broad range of needs from sales and marketing agreements in APAC, privacy and cybersecurity policies, risk mitigation to supporting IP acquisition and potential commercial or IP litigation in China.
Responsible for drafting, negotiation and execution of sales related commercial contracts and other customer-orientated agreements. Involves independent judgement and analysis of contracts, including identification of legal and business- related issues and their resolution.
Oxford Nanopore’s sequencing technology has evolved substantially over recent years and is now both competitive on traditional market metrics, as well as offering disruptive features (real-time, scalability, adaptive sampling, methylation, and direct RNA). These breakthrough features can lead to a true reshaping of the market of genomic analysis. To reflect the development of the technology, Oxford Nanopore is driving an expansion of the customer base beyond a research users, to applied industrial, clinical and biopharma users.
Key Duties & Responsibilities:
PERSON SPECIFICATION
Essential
Qualifications/ Education
Experience
Knowledge/Skills/
Abilities
Attitude/Other
Requirements
#LI-MW1

Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.